Opinion|Videos|January 13, 2025
Impact of Recurrent C Difficile Infection on Costs and Patient Quality of Life
Author(s)Sahil Khanna, MBBS, MS
The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource utilization while severely compromising patient quality of life through persistent physical symptoms, psychological distress, and substantial social disruptions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does recurrent C difficile infection impact health care resources utilization and other medical costs?
- What are the ways in which recurrent C difficile infection can adversely impact a patient’s quality of life?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5